CL
CLRB.US Cellectar Biosciences Inc
- Market cap
- USD 11.4M
- P/E
- -
- P/B
- 0.52x
- ROE
- -122.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CLRB.US undervalued?
Graham numberThe Graham number of Cellectar Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cellectar Biosciences Inc fundamental analysis
No fundamental analysis for Cellectar Biosciences Inc yet.
Cellectar Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple …
Full company profileCellectar Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cellectar Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -357K | -1.55M | -82.3K | -189K | -208K | -228K | -239K | -192K | -292K | -214K | - |
| Operating Income | -9.45M | -13.6M | -13.3M | -14.2M | -15.3M | -24.1M | -28.8M | -39.0M | -51.8M | -23.0M | -28.1M |
| EBITDA | -9.09M | -12.1M | -13.2M | -14.0M | -15.0M | -24.0M | -28.7M | -42.6M | -44.2M | -21.6M | -27.7M |
| Net Income | -6.18M | -13.6M | -13.2M | -14.1M | -15.1M | -24.0M | -28.6M | -42.8M | -44.6M | -21.8M | -27.4M |
| EPS | -4,248 | -2,900 | -1,341 | -551 | -229 | -130 | -122 | -105 | -36 | -8.35 | -1.57 |
| Balance Sheet | |||||||||||
| Total Assets | 15.3M | 12.9M | 15.1M | 12.3M | 58.7M | 37.2M | 21.6M | 12.1M | 25.5M | 15.0M | 29.7M |
| Total Liabilities | 1.78M | 2.12M | 1.79M | 3.19M | 3.86M | 4.16M | 12.1M | 25.9M | 11.2M | 5.06M | 7.33M |
| Shareholders' Equity | 13.5M | 10.8M | 13.3M | 9.06M | 54.8M | 33.0M | 9.54M | -13.8M | 14.3M | 9.92M | 22.4M |
| Cash & Short-term Investments | 11.4M | 10.0M | 13.3M | 10.6M | 57.2M | 35.7M | 19.9M | 9.56M | 23.3M | 13.2M | 24.6M |
| Total Debt | 94.6K | 5.25K | 2.21K | 528K | 422K | 302K | 604K | 553K | 494K | 410K | 1.53M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.28M | -11.0M | -11.4M | -11.7M | -13.9M | -22.6M | -25.2M | -32.4M | -47.6M | -23.1M | -27.0M |
| Capital Expenditure | 72.3K | 347K | 385K | 24.5K | 62.4K | 141K | 226K | 864K | 104K | 5.88K | 4.50K |
| Free Cash Flow | -8.35M | -11.4M | -11.8M | -11.7M | -14.0M | -22.7M | -25.4M | -33.2M | -47.7M | -23.1M | -27.0M |
| Ratios | |||||||||||
| ROE | -45.6% | -126.1% | -99.8% | -155.6% | -27.5% | -72.5% | -300.0% | - | -311.9% | -219.7% | -122.3% |
| ROA | -40.3% | -105.4% | -87.9% | -115.0% | -25.7% | -64.4% | -132.5% | -354.2% | -175.0% | -145.5% | -92.2% |
| Debt to Equity | 0.01x | 0.00x | 0.00x | 0.06x | 0.01x | 0.01x | 0.06x | - | 0.03x | 0.04x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cellectar Biosciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 2.24M | 227 | - |
| 2017 | USD 1.45M | 310 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Jun 24, 2025.
Who owns Cellectar Biosciences Inc
- Insiders 1.65%
- Institutions 31.04%
- Public & others 67.31%
- Shares outstanding 10.0M
- Free float 9.86M
Top funds holding CLRB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 184K | 1.95% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 46.9K | 0.50% | -0.38% | Sep 2026 |
| Abante Quant Value FI | 36.3K | 0.38% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 10.5K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 3.59K | 0.04% | 0.00% | Sep 2026 |
Top institutions holding CLRB.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Caligan Partners LP | 470K | 4.97% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 440K | 4.66% | 0.00% | Jun 2026 |
| StemPoint Capital LP | 355K | 3.76% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 327K | 3.46% | +299.79% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 322K | 3.40% | 0.00% | Jun 2026 |
| Bleichroeder LP | 289K | 3.05% | +188.68% | Jun 2026 |
| Jupiter Topco LLC | 274K | 2.90% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 220K | 2.33% | 0.00% | Jun 2026 |
| Empery Asset Management, LP | 190K | 2.01% | 0.00% | Jun 2026 |
| Diadema Partners LP | 138K | 1.46% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 105K | 1.11% | 0.00% | Jun 2026 |
| Persistent Asset Partners Limited | 93.0K | 0.98% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 85.1K | 0.90% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 53.4K | 0.56% | +1.09% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 46.2K | 0.49% | +178.89% | Jun 2026 |
| Sequoia Financial Advisors LLC | 21.9K | 0.23% | +15.92% | Jun 2026 |
| Acadian Asset Management LLC | 16.6K | 0.18% | 0.00% | Jun 2026 |
| Northern Trust Corp | 14.8K | 0.16% | 0.00% | Jun 2026 |
| Riverview Capital Advisers LLC | 10.4K | 0.11% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.74K | 0.05% | -0.21% | Jun 2026 |
Cellectar Biosciences Inc company profile
- Company name
- Cellectar Biosciences Inc
- Ticker
- CLRB.US
- Exchange
- USA Stocks
- Listed since
- Nov 10, 2005
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- 100 Campus Drive, Florham Park, NJ, United States, 07932
- Phone
- 608 441 8120
- Website
- cellectar.com
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Cellectar Biosciences Inc management
3- Mr. James V. CarusoPresident, CEO & Director · born 1959
- Mr. Chad J. Kolean CPAVP, CFO & Secretary · born 1964
- Mr. Jarrod LongcorChief Operating Officer · born 1973